Chemotherapy With Anlotinib in Advanced Cervical Cancer

Inclusion Criteria: * Patients with advanced (metastatic, persistent, and recurrent) cervical cancer confirmed by imaging and unsuitable for surgery and radiotherapy . * Eastern Cooperative Oncology Group (ECOG) Performance Score(PS) 0-1 * Estimated life expectancy \> 3 months * Adequate bone marrow function: hemoglobin \> 90 g/L, absolute neutrophil count(ANC) \> 1.5 × 10\^9/L, platelet \> 80 × 10\^9/L); * Adequate hepatic function: total bilirubin \< 1.5 times the upper limit of normal (ULN), alanine aminotransferase (ALT) and aspartate aminotransferase (AST)\<2.5×ULN or \<5×ULN for patients with liver metastases; * Adequate renal function: serum creatinine \< 1.5 × ULN or creatinine clearance rate (CCR) \>60 mL/min; * Adequate cardiac function: left ventricular ejection fraction (LVEF) \> 50%. Exclusion Criteria: * Preexisting thyroid disease, thyroid function cannot be maintained in the normal range after treatment; * Have used other anti-VEGF or VEGFR-targeted drugs or received immunotherapy; * A history of major surgical treatment within 4 weeks, radiotherapy within 3 weeks, and concurrent chemoradiotherapy within 6 weeks; * Receiving hormone or immunosuppressive therapy for various reasons; * Inability to swallow oral medication; * Any malabsorption; * Diseases diagnosed as severe or uncontrollable within 6 months prior to the first day of treatment. * Participate in clinical trials of other antitumor drugs within 28 days prior to the start of study treatment; * The patient has comorbidities that may endanger the patient's safety or affect the patient's ability to complete the study. * According to the researcher's judgment, the patient has an accompanying disease that may jeopardize the patient's safety or affect the patient's ability to complete the study in the investigator's judgment.